US Pharma MarketingMigraine biotech makes its debut with $46M to advance preclinical pipeline
Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine prevention. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely.
Available treatments for migraine typically only reduce attack frequencies ...
Source: Endpoints News